The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Cited by
Items 201–300 of 1,000
Franch‐Nadal, J., Menéndez, S. A., Espino, J. D., & Mata‐Cases, M. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.06.033 · Cited by 81
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Yang, X., So, W., Kong, A. P. S., Clarke, P., Ho, C. S., Lam, C. W. K., Ng, M. H. L., Lyu, R., Yin, D., Chow, C. C., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0376-3 · Cited by 82
“Guzder et al. [27] validated the Framingham CHD risk equation and the UKPDS CHD risk engines using a UK community-based cohort and found that the two sets of risk functions had similar discriminative power (Framingham, 0.66; UKPDS, 0.67).”
BackgroundInfluentialSmoking Amplifies Cardiovascular Risk in Patients With Hypertension and Diabetes
Fagard, R. H. (2009) · Diabetes Care · doi:10.2337/dc09-s354 · Cited by 77
“The studies include the First National Health and Nutrition Examination Survey (13), a large case-control study (14), the World Health Organization Multinational Study of Vascular Disease in Diabetes (15,16), the U.K. Prospective Diabetes Study (UKPDS) (17–19), the Nurses’ Health Study Cohort (20,21), and the Swedish…”
BackgroundInfluentialYu, J., Shah, B. M., Ip, E. J., & Chan, J. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.102 · Cited by 88
Neto, P. R. O., Marušić, S., de Lyra, D. P., Pilger, D. A., Cruciol-Souza, J. M., Gaeti, W. P., & Cuman, R. K. N. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3259q · Cited by 82
On behalf of the Australasian Peers for Progress Diabetes Project Investigators, Aziz, Z., Riddell, M. A., Absetz, P., Brand, M., & Oldenburg, B. (2018) · BMC Public Health · doi:10.1186/s12889-018-5148-8 · Cited by 68
Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah‐Muthu, S. S., Colhoun, H. M., Lawrenson, R. A., & de Vries, C. S. (2008) · Diabetologia · doi:10.1007/s00125-008-1076-y · Cited by 84
Batsis, J. A., & Lopez-Jimenez, F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-29 · Cited by 71
Using the EQ-5D Index Score as a Predictor of Outcomes in Patients With Type 2 Diabetes
Clarke, P., Hayes, A., Glasziou, P., Scott, R. S., Simes, R. J., & KEECH, A. C. (2008) · Medical Care · doi:10.1097/mlr.0b013e3181844855 · Cited by 82
“These factors were chosen as they have been shown to be significant predictors of diabetes related complications in previous risk models based on the UKPDS.(9,10) Following a similar approach to the development of other risk models(18) factors were dropped through backwards stepwise elimination if their HRs were not s…”
MethodGurka, M. J., Guo, Y. M., Filipp, S. L., & DeBoer, M. D. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0647-y · Cited by 85
“systems specifically designed to predict CHD in Type 2 diabetes [38], this MetS severity score was designed to estimate MetS severity—potentially as a means of estimating the processes behind MetS [9–11].”
BackgroundOutcomes from a Multiple Risk Factor Diabetes Self-Management Trial for Latinas: ¡Viva Bien!
Toobert, D. J., Strycker, L. A., Barrera, M., Osuna, D., King, D. K., & Glasgow, R. E. (2011) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9256-7 · Cited by 72
“Tenyear heart disease risk was assessed using the United Kingdom Prospective Diabetes Study logistic equation [50].”
MethodRiemsma, R., Corro Ramos, I., Birnie, R., Büyükkaramikli, N., Armstrong, N., Ryder, S., Duffy, S., Worthy, G., Al, M., Severens, J., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20170 · Cited by 73
Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
van der Leeuw, J., Beulens, J. W. J., van Dieren, S., Schalkwijk, C. G., Glatz, J. F. C., Hofker, M. H., Verschuren, W. M. M., Boer, J. M. A., van der Graaf, Y., Visseren, F. L. J., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003048 · Cited by 77
“The base model included predictors of the United Kingdom Prospective Diabetes Study algorithm (age at diabetes diagnosis, duration of diagnosed diabetes, sex, smoking, glycated hemoglobin (HbA1c), systolic blood pressure, total cholesterol/high-density lipoprotein (HDL) cholesterol ratio), and 2 additional variables (…”
Markov Decision Processes for Screening and Treatment of Chronic Diseases
Steimle, L. N., & Denton, B. T. (2017) · International series in management science/operations research/International series in operations research & management science · doi:10.1007/978-3-319-47766-4_6 · Cited by 95
“For instance, statistical models for type 2 diabetes include: the Framingham model [26, 27, 28], the UKPDS model [29, 30, 31, 32], and the ACC/AHA pooled risk calculator [33].”
MethodRisk prediction of complications of metabolic syndrome before and 6 years after gastric bypass
Aminian, A., Daigle, C. R., Romero‐Talamás, H., Kashyap, S. R., Kirwan, J. P., Brethauer, S. A., & Schauer, P. R. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.01.025 · Cited by 75
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 83
Koelewijn-van Loon, M. S., van der Weijden, T., van Steenkiste, B., Ronda, G., Winkens, B., Severens, J. L., Wensing, M., Elwyn, G., & Grol, R. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081591 · Cited by 75
“• Risk assessment (intervention and control): The absolute 10-year mortality risk from cardiovascular diseases was assessed with use of a risk table from the Dutch guidelines (for patients without diabetes) or the UK Prospective Diabetes Study risk engine (for patients with diabetes).(6,23) Nurses in the control group…”
MethodLagani, V., Chiarugi, F., Thomson, S., Fursse, J., Lakasing, E., Jones, R. W., & Tsamardinos, I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.03.001 · Cited by 74
Cheng, F., Luk, A. O. Y., Tam, C. H. T., Fan, B., Wu, H., Yang, A., Lau, E. S. H., Ng, A. C. W., Lim, C. K. P., Lee, H. M., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0028 · Cited by 76
Pugliese, G., Solini, A., Bonora, E., Orsi, E., Zerbini, G., Giorgino, F., Cavalot, F. L., Pontiroli, A. E., Baroni, M. G., Morano, S., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.035 · Cited by 79
Taveira, T. H., Dooley, A. G., Cohen, L. B., Khatana, S. A. M., & Wu, W.-C. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q212 · Cited by 71
Guo, V. Y., Cao, B., Wu, X., Lee, J. J. W., & Zee, B. C.-Y. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.03.009 · Cited by 77
Economics of Team-based Care in Controlling Blood Pressure
Jacob, V., Chattopadhyay, S. K., Thota, A. B., Proia, K. K., Njie, G. J., Hopkins, D. P., Finnie, R. K. C., Pronk, N. P., & Kottke, T. E. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.04.003 · Cited by 80
Global cardiovascular disease risk assessment in United States adults with diabetes
Wong, N. D., Glovaci, D., Wong, K., Malik, S., Franklin, S. S., Wygant, G., & Iloeje, U. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112436403 · Cited by 69
Assessment of Cardiovascular Disease Risk in South Asian Populations
Hussain, S. M., Oldenburg, B. F., Wang, Y., Zoungas, S., & Tonkin, A. M. (2013) · International Journal of Vascular Medicine · doi:10.1155/2013/786801 · Cited by 79
“This paper examines the implications of CVD risk algorithms because of the potential limitations in current CVD risk assessment approaches for prevention and control of atherosclerotic CVD in South Asian populations.”
BackgroundAhmad, A., Lim, L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2024) · Communications Medicine · doi:10.1038/s43856-023-00429-z · Cited by 82
Chung, S., Yang, C.-C., Chen, C.-C., Hsu, Y.-C., & Lei, M. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29926 · Cited by 74
Parchman, M. L., Zeber, J. E., Romero, R. R., & Pugh, J. A. (2007) · Medical Care · doi:10.1097/mlr.0b013e318148431e · Cited by 70
“0.(12) The values obtained from UKPDS risk engine are based on weightings of fixed risk factors: age, duration of diabetes, sex, ethnicity, and the presence of atrial fibrillation, and modifiable risk factors: A1c, systolic BP, total cholesterol, HDL cholesterol, and smoking status.”
MethodSmoking and diabetes—The double health hazard!
Fagard, R. H., & Nilsson, P. M. (2009) · Primary care diabetes · doi:10.1016/j.pcd.2009.09.003 · Cited by 90
van der Leeuw, J., Ridker, P. M., van der Graaf, Y., & Visseren, F. L. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu004 · Cited by 67
Osonoi, Y., Mita, T., Osonoi, T., Saito, M., Tamasawa, A., Nakayama, S., Someya, Y., Ishida, H., Kanazawa, A., Gosho, M., et al. (2014) · Chronobiology International · doi:10.3109/07420528.2014.943843 · Cited by 68
“Furthermore, the incidences of cardiovascular disease (CVD) and microvascular events correlate with lifestyle factors in patients with T2DM (Balkau et al., 2004; Stevens et al., 2001).”
BackgroundPadwal, R. S., Hemmelgarn, B. R., Khan, N. A., Grover, S. A., McKay, D. W., Wilson, T. W., Penner, B., Burgess, E. D., McAlister, F. A., Bolli, P., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70491-x · Cited by 92
“uk/index) (20,21) and the Symptoms-CausesOutput-Resources-Effects (SCORE) model (www.”
Buyken, A. E., von Eckardstein, A., Schulte, H., Cullen, P., & Assmann, G. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3280142037 · Cited by 80
Biswas, M., Saba, L., Omerzu, T., Johri, A. M., Khanna, N. N., Višković, K., Mavrogeni, S. I., Laird, J. R., Pareek, G., Miner, M. M., et al. (2021) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-021-00461-2 · Cited by 75
Gori, M., Gupta, D. K., Claggett, B. L., Selvin, E., Folsom, A. R., Matsushita, K., Bello, N. A., Cheng, S. C., Shah, A. M., Skali, H., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1760 · Cited by 71
Payne, R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04219.x · Cited by 91
10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Gyldenkerne, C., Mortensen, M. B., Kahlert, J. A., Thrane, P. G., Olesen, K. K. W., Sørensen, H. T., Thomsen, R. W., & Mæng, M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.015 · Cited by 76
Case Management to Reduce Risk of Cardiovascular Disease in a County Health Care System
Ma, J. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.381 · Cited by 69
Can Self-Rated Health Scores Be Used for Risk Prediction in Patients With Type 2 Diabetes?
Hayes, A., Clarke, P., Glasziou, P., Simes, R. J., Drury, P., & KEECH, A. C. (2008) · Diabetes Care · doi:10.2337/dc07-1391 · Cited by 72
Duration of Diabetes and Incident Heart Failure
Echouffo-Tcheugui, J. B., Zhang, S., Florido, R., HAMO, C. E., Pankow, J. S., Michos, E. D., Goldberg, R. B., Nambi, V., Gerstenblith, G., Post, W. S., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.005 · Cited by 81
Denig, P., Schuling, J., Haaijer-Ruskamp, F., & Voorham, J. (2014) · BMJ · doi:10.1136/bmj.g5651 · Cited by 65
The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus
van der Leeuw, J., van Dieren, S., Beulens, J. W. J., Boeing, H., Spijkerman, A. M. W., van der Graaf, Y., van der A, D. L., Nöthlings, U., Visseren, F. L. J., Rutten, G. E. H. M., et al. (2015) · Heart · doi:10.1136/heartjnl-2014-306068 · Cited by 69
“Including all endpoints that occurred during follow-up, the c-statistics decreased slightly in the EPIC-NL and EPIC-Potsdam cohorts, whereas they increased for SMART (see online supplementary eFigures 7 and 8).”
Yeboah, J., Erbel, R., Delaney, J. C., Nance, R., Guo, M., Bertoni, A. G., Budoff, M., Moebus, S., Jöckel, K.-H., Burke, G. L., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.035 · Cited by 70
Song, S. H., & Brown, P. M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01116.x · Cited by 68
Hemmelgarn, B. R., McAlister, F. A., Grover, S. A., Myers, M. G., McKay, D. W., Bolli, P., Abbott, C. B., Schiffrin, E. L., Honos, G. N., Burgess, E. D., et al. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70279-3 · Cited by 78
Yang, X., Ronald, C. W., So, W., Kong, A. P. S., Ko, G. T. C., Ho, C.-S., Lam, C. W. K., Cockram, C. S., Tong, P. C. Y., & Chan, J. C. N. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-9 · Cited by 73
Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes
on behalf of the SUMMIT Investigators, Looker, H. C., Colombo, M., Agakov, F., Zeller, T., Groop, L., Thorand, B., Palmer, C. N., Hamsten, A., de Faire, U., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3535-6 · Cited by 66
“Choice of covariates in the baseline model Clinical covariates included in the models for biomarker selection were selected based upon their inclusion in existing CVD risk engines [12, 13] or known associations with CVD in type 2 diabetes and their availability for all cohorts.”
MethodGreenhalgh, T., Campbell-Richards, D., Vijayaraghavan, S., Collard, A., Malik, F. A., Griffin, M., Morris, J. H., Claydon, A., & Macfarlane, F. (2011) · Journal of Health Services Research & Policy · doi:10.1258/jhsrp.2010.009159 · Cited by 77
Cameron, C., Coyle, D., Ur, E., & Klarenbach, S. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090765 · Cited by 66
Jamthikar, A. D., Gupta, D., Saba, L., Khanna, N. N., Viskovic, K., Mavrogeni, S., Laird, J. R., Sattar, N., Johri, A. M., Pareek, G., et al. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104043 · Cited by 61
Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view
Wilson, P. W. F. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.012 · Cited by 65
“For persons with T2DM, British investigators have developed a CHD risk equation, and this approach includes HbA1C and duration of diabetes mellitus [54].”
Backgroundvon Eynatten, M., Liu, D., Hock, C., Oikonomou, D., Baumann, M., Allolio, B., Korosoglou, G., Morcos, M., Câmpean, V., Amann, K., et al. (2009) · Diabetes · doi:10.2337/db09-0204 · Cited by 72
Webb, D. R., Gray, L. J., Khunti, K., Srinivasan, B. T., Taub, N. A., Campbell, S., Barnett, J., Farooqi, A., Echouffo-Tcheugui, J. B., Griffin, S. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2189-2 · Cited by 76
“The UK Prospective Diabetes Study (UKPDS) score uses age, duration of diabetes, sex, ethnicity, smoking status, systolic blood pressure, HbA1c, total cholesterol and HDL cholesterol [19, 20].”
BackgroundThe Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock
Kengne, A. P., Turnbull, F., & MacMahon, S. W. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.02.010 · Cited by 76
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192640 · Cited by 68
Major complications have an impact on total annual medical cost of diabetes
Morsanutto, A., Berto, P., Lopatriello, S., Gelisio, R., Voinovich, D., Cippo, P. P., & Mantovani, L. G. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.06.011 · Cited by 84
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Development of Health Parameter Model for Risk Prediction of CVD Using SVM
Unnikrishnan, P., Kumar, D. K., Poosapadi Arjunan, S., Kumar, H., Mitchell, P., & Kawasaki, R. (2016) · Computational and Mathematical Methods in Medicine · doi:10.1155/2016/3016245 · Cited by 62
Lagani, V., Koumakis, L., Chiarugi, F., Lakasing, E., & Tsamardinos, I. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.11.003 · Cited by 67
Gulati, G., Upshaw, J., Wessler, B. S., Brazil, R. J., Nelson, J., van Klaveren, D., Lundquist, C. M., Park, J. G., McGinnes, H., Steyerberg, E. W., et al. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008487 · Cited by 55
Cosmo, S. D., Copetti, M., Lamacchia, O., Fontana, A., Massa, M., Morini, E., Pacilli, A., Fariello, S., Palena, A. P., Rauseo, A., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1906 · Cited by 66
Perera, R., McFadden, E., McLellan, J., Lung, T., Clarke, P., Pérez, T., Fanshawe, T., Dalton, A., Farmer, A., Glasziou, P., et al. (2015) · Health Technology Assessment · doi:10.3310/hta191000 · Cited by 62
Self-citationOsonoi, Y., Mita, T., Osonoi, T., Saito, M., Tamasawa, A., Nakayama, S., Someya, Y., Ishida, H., Kanazawa, A., Gosho, M., et al. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0026-1 · Cited by 67
Eliasson, B., Guðbjörnsdóttir, S., Zethelius, B., Eeg‐Olofsson, K., & Cederholm, J. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313494292 · Cited by 62
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010207 · Cited by 61
“Thus, age represents a major determinant of the prognostic information included in all estimation risk models [36], whereas modifiable factors, such as body weight, play only a marginal role [22,40].”
BackgroundMethodMarini, S., Trifoglio, E., Barbarini, N., Sambo, F., Di Camillo, B., Malovini, A., Manfrini, M., Cobelli, C., & Bellazzi, R. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.08.021 · Cited by 61
“Other useful instruments are represented by the UK Prospective Diabetes Study (UKPDS) Outcomes Model [16–18] and by the UKPDS Risk Engine [19], both specific for the progression of T2D.”
MethodSharma, A., Zheng, Y., Ezekowitz, J. A., Westerhout, C. M., Udell, J. A., Goodman, S. G., Armstrong, P. W., Buse, J. B., Green, J. B., Josse, R. G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2806 · Cited by 67
Bansal, S., Wackers, F. J. T., Inzucchi, S. E., Chyun, D. A., Davey, J. A., Staib, L. H., Young, L. H., & for the DIAD Study Investigators (2010) · Diabetes Care · doi:10.2337/dc10-1194 · Cited by 61
Metabolic syndrome: Evaluation of pathological and therapeutic outcomes
Miranda, P. J., DeFronzo, R. A., Califf, R. M., & Guyton, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.012 · Cited by 68
Cardiovascular Risk Stratification and Management in Pre-Diabetes
Færch, K., Vistisen, D., Johansen, N. B., & Jørgensen, M. E. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0493-1 · Cited by 64
the J-EVT and J-PCI investigators, Takahara, M., Iida, O., Kohsaka, S., Soga, Y., Fujihara, M., Shinke, T., Amano, T., & Ikari, Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0955-5 · Cited by 59
Risk scoring in the assessment of cardiovascular risk
Beswick, A., & Brindle, P. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236362.56216.44 · Cited by 57
Predicting major outcomes in type 1 diabetes: a model development and validation study
Soedamah‐Muthu, S. S., Vergouwe, Y., Costacou, T., Miller, R. G., Zgibor, J. C., Chaturvedi, N., Snell‐Bergeon, J. K., Maahs, D. M., Rewers, M., Forsblom, C. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3358-x · Cited by 63
“A number of prognostic models for the major outcome CHD have been evaluated [28–32], but only a few specifically for type 1 diabetes [12].”
MethodMason, J. E., Denton, B. T., Shah, N. D., & Smith, S. (2013) · European Journal of Operational Research · doi:10.1016/j.ejor.2013.09.018 · Cited by 69
Yaturu, S., Rains, J., & Jain, S. K. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.471 · Cited by 67
Steps, moderate-to-vigorous physical activity, and cardiometabolic profiles
Hajna, S., Ross, N. A., & Dasgupta, K. (2018) · Preventive Medicine · doi:10.1016/j.ypmed.2017.11.007 · Cited by 52
Yozgatlı, T. K., Lefrandt, J. D., Noordzij, M. J., Oomen, P. H. N., Brouwer, T., Jäger, J., Cabezas, M. C., & Smit, A. J. (2018) · Diabetic Medicine · doi:10.1111/dme.13651 · Cited by 61
Chowdhury, M. Z. I., Yeasmin, F., Rabi, D. M., Ronksley, P. E., & Turin, T. C. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.10.010 · Cited by 57
Holman, R. R., Coleman, R. L., Shine, B. S. F., & Stevens, R. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1796 · Cited by 58
Self-citationBiomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes
Bachmann, K. N., & Wang, T. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4442-9 · Cited by 61
Mueller, E., Maxion‐Bergemann, S., Gultyaev, D., Walzer, S., Freemantle, N., Mathieu, C., Bolinder, B., Gerber, R. A., Kvasz, M., & Bergemann, R. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.219 · Cited by 63
Snel, M., van Diepen, J. A., Stijnen, T., Pijl, H., Romijn, J. A., Meinders, A. E., Voshol, P. J., & Jazet, I. M. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.09.032 · Cited by 57
A Pilot Study of the Duodenal-Jejunal Bypass Liner in Low Body Mass Index Type 2 Diabetes
COHEN, R. V., Neto, M. G., Correa, J. L., Sakai, P., Martins, B. D. C., Schiavon, C. A., Petry, T. B. Z., Salles, J. E. N., Aboud, C. M., & SORLI, C. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2814 · Cited by 58
“Although the present study was not designed to measure the effect of treatment on the incidence of coronary events, the change in risk profile due to changes in diabetes status (i.e., HbA1c levels and plasma lipids (17) of individual study subjects) can be estimated using The UK Prospective Diabetes Study Risk Engine…”
MethodSathyapalan, T., Rigby, A. S., Bhasin, S., Thatcher, N. J., Kilpatrick, E. S., & Atkin, S. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2875 · Cited by 57
Simpson, S. H., Lier, D. A., Majumdar, S. R., Tsuyuki, R. T., Lewanczuk, R. Z., Spooner, R., & Johnson, J. A. (2015) · Diabetic Medicine · doi:10.1111/dme.12692 · Cited by 55
What determines the cost-effectiveness of diabetes screening?
Glümer, C., Yuyun, M., Griffin, S., Farewell, D., Spiegelhalter, D., Kinmonth, A. L., & Wareham, N. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0248-x · Cited by 54
“The untreated risk model uses the risk prediction engine derived from the UK Prospective Diabetes Study (UKPDS), calculating the 5-year cumulative risk of CHD events (fatal or non-fatal myocardial infarction or sudden death) in people with diabetes (Table 1) [10].”
MethodWelschen, L. M. C., van Oppen, P., Bot, S. D. M., Kostense, P. J., Dekker, J. M., & Nijpels, G. (2012) · Journal of Behavioral Medicine · doi:10.1007/s10865-012-9451-z · Cited by 58
“The 10-year risk of developing a CHD event was calculated at baseline and at 12 months using the UK Prospective Diabetes Study (UKPDS) risk engine (Stevens et al., 2001).”
MethodVascular Calcification in Diabetes: Mechanisms and Implications
Snell‐Bergeon, J. K., Budoff, M. J., & Hokanson, J. E. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0379-7 · Cited by 56
“The UKPDS Risk Engine [15] was designed specifically to address risk stratification in people with diabetes more accurately than the Framingham risk score, but it was developed in adults over 30, and so cannot be used in many patients with T1D and an increasing number of young patients with T2D.”
Loon, M. S. K.-V., van Steenkiste, B., Ronda, G., Wensing, M., Stoffers, J., Elwyn, G. J., Grol, R. P. T. M., & van der Weijden, T. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-9 · Cited by 67
Riddell, M. C., & Burr, J. F. (2011) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h11-063 · Cited by 69
Khanna, N. N., Jamthikar, A. D., Araki, T., Gupta, D., Piga, M., Saba, L., Carcassi, C., Nicolaides, A. N., Laird, J. R., Suri, H. S., et al. (2019) · Echocardiography · doi:10.1111/echo.14242 · Cited by 56
Davis, W. A., Colagiuri, S., & Davis, T. M. E. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02684.x · Cited by 55
Value of Lifestyle Intervention to Prevent Diabetes and Sequelae
Dall, T. M., Storm, M. V., Semilla, A. P., Wintfeld, N., O’Grady, M., & Venkat Narayan, K. M. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.10.003 · Cited by 53
Agarwala, A., Satish, P., Rifai, M. A., Mehta, A., Cainzos‐Achirica, M., Shah, N. S., Kanaya, A. M., Sharma, G. V., Dixon, D. L., Blumenthal, R. S., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100258 · Cited by 57
Li, G., Lü, W., Ai, R., Yang, J., Fang, C., & Tang, Z. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-52 · Cited by 58
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.019 · Cited by 66
Orlistat: A Review of its Use in the Management of Patients with Obesity
Curran, M. P., & Scott, L. J. (2004) · Drugs · doi:10.2165/00003495-200464240-00010 · Cited by 65
Wan, Q., Harris, M. F., Jayasinghe, U. W., Flack, J., Georgiou, A., Penn, D. L., & Burns, J. R. (2006) · BMJ Quality & Safety · doi:10.1136/qshc.2005.014845 · Cited by 52
Rahman, M., Simmons, R. K., Hennings, S., Wareham, N. J., & Griffin, S. J. (2012) · Diabetologia · doi:10.1007/s00125-011-2441-9 · Cited by 56
“Cardiovascular disease Cardiovascular disease was assessed using three methods: (1) self-report from the Rose angina questionnaire: a score >3 was defined as the presence of clinical ischaemic heart disease (IHD) [17, 18]; (2) a 12-lead ECG, which was graded using the Minnesota coding system [19]; (3) 10-year modelled…”
Method
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.